Since 2011, Vemurafenib (BRAF inhibitor), Trametinib (MEK inhibitor), Ipilimumab (cytotoxic T-lymphocyte-associated protein 4 monoclonal antibody), as well as Nivolumab and Pembrolizumab (programmed cell death protein 1 monoclonal antibodies) have been successively approved by the US Federal Drug Administration for melanoma treatment. This evidence concerns the gene BRAF and melanoma.